Medicare Enrolled
Dr. Vijai Daniel, M.D, MPH
Critical Care Medicine · Fresno, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Daniel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Daniel?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Daniel
Dr. Vijai Daniel is a critical care medicine specialist in Fresno, CA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Daniel performed 2,991 Medicare services across 2,271 unique beneficiaries.
Between the years covered by Open Payments, Dr. Daniel received a total of $436,926 from 52 pharmaceutical and/or device companies across 960 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in critical care medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Daniel is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 8% volume in CA
$436,926 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,991
Medicare services
Top 8% in CA for critical care medicine
2,271
Unique beneficiaries
$88
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~176 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
981 | $101 | $166 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
270 | $130 | $251 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
264 | $144 | $238 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
221 | $63 | $117 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
205 | $32 | $172 |
| Spirometry test A test that measures the amount of air you can exhale and how fast you can blow it out. The provider evaluates the results to check lung function. |
204 | $20 | $62 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
203 | $37 | $102 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
203 | $47 | $110 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
107 | $168 | $443 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
73 | $95 | $183 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
72 | $98 | $299 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
63 | $138 | $291 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
50 | $94 | $300 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing, airflow, and physical effort during sleep. |
43 | $48 | $350 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
18 | $103 | $381 |
| Bronchoscopy A diagnostic exam of the lung airways using an endoscope to visually inspect the inside of the lungs and airways. |
14 | $103 | $350 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$436,926
Total received (2018-2024)
Avg $62,418/year across 7 years
Top 1% in CA for critical care medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
960
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$414,178 (94.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$14,259 (3.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,489 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$94,527
2023
$112,831
2022
$71,259
2021
$23,923
2020
$64,107
2019
$58,809
2018
$11,470
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$93,024
AstraZeneca Pharmaceuticals LP
$512
Merck Sharp & Dohme LLC
$159
Baxter Healthcare
$131
Philips North America LLC
$122
Insmed, Inc.
$107
HARMONY BIOSCIENCES LLC
$100
Boehringer Ingelheim Pharmaceuticals, Inc.
$76
Actelion Pharmaceuticals US, Inc.
$45
Electromed, Inc.
$45
Astellas Pharma US Inc
$44
GENZYME CORPORATION
$40
United Therapeutics Corporation
$24
Mylan Specialty L.P.
$24
Fisher & Paykel Healthcare Inc
$22
Paratek Pharmaceuticals, Inc.
$20
Vifor Pharma, Inc.
$16
Amgen Inc.
$16
Top 3 companies account for 99.1% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$423,055
AstraZeneca Pharmaceuticals LP
$6,547
Boehringer Ingelheim Pharmaceuticals, Inc.
$720
Actelion Pharmaceuticals US, Inc.
$530
Genentech USA, Inc.
$500
Astellas Pharma US Inc
$352
Sunovion Pharmaceuticals Inc.
$342
Merck Sharp & Dohme LLC
$325
Philips Electronics North America Corporation
$323
Regeneron Healthcare Solutions, Inc.
$272
Electromed, Inc.
$239
Resmed Corp
$235
HARMONY BIOSCIENCES LLC
$233
Baxter Healthcare
$226
United Therapeutics Corporation
$219
Insmed, Inc.
$210
Advanced Respiratory, Inc
$194
Gilead Sciences, Inc.
$193
Allergan, Inc.
$174
Mylan Specialty L.P.
$166
Otsuka America Pharmaceutical, Inc.
$159
Mallinckrodt Hospital Products Inc.
$142
Harmony Biosciences LLC
$127
Philips North America LLC
$122
Allergan Inc.
$119
AbbVie Inc.
$97
Fisher & Paykel Healthcare Inc
$94
E.R. Squibb & Sons, L.L.C.
$91
Teva Pharmaceuticals USA, Inc.
$78
Circassia Pharmaceuticals Inc
$76
Grifols USA, LLC
$70
ABBVIE INC.
$68
GENZYME CORPORATION
$66
Bayer HealthCare Pharmaceuticals Inc.
$61
Janssen Pharmaceuticals, Inc
$61
Merck Sharp & Dohme Corporation
$55
Shire North American Group Inc
$53
ANI Pharmaceuticals, Inc.
$37
Ceribell, Inc.
$32
ADVANCED RESPIRATORY, INC
$29
Amgen Inc.
$28
Edwards Lifesciences Corporation
$25
PFIZER INC.
$24
EKOS Corporation
$23
La Jolla Pharmaceutical Company
$22
Paratek Pharmaceuticals, Inc.
$20
Inspire Medical Systems, Inc.
$18
Vifor Pharma, Inc.
$16
Takeda Pharmaceuticals U.S.A., Inc.
$16
Ambu Inc.
$16
Melinta Therapeutics, Inc.
$15
Medtronic, Inc.
$14
Top 3 companies account for 98.5% of all-time payments
Associated products mentioned in payments ›
(7999) SRC Und · (8874) inCourage · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Adempas · AirDuo Digihaler · AirFit · AirSense · Arikayce · Astral · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHANTIX · CINQAIR · Ceribell Rapid Response EEG · Cresemba · DUAKLIR PRESSAIR · DUPIXENT · EKOSONIC · ELIQUIS · EV1000 Clinical Platform · Esbriet · FASENRA · FISHER & PAYKEL HEALTHCARE · GIAPREZA · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Monarch Airway Clearance System · Hillrom - Vest System Model 105 Home Care · INSPIRE · LONHALA MAGNAIR · Letairis · NUCALA · NUZYRA · OFEV · OPSUMIT · ORENITRAM · Obstructive Sleep Apnea Device or Hospital Respiratory Equipment · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C · Prolastin-C Liquid · REMODULIN · Respiratoriy Care Undiv · SAMSCA · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TAVNEOS · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · UPTRAVI · UTIBRON · VERQUVO · Vabomere · WAKIX · WINREVAIR · Wakix · XARELTO · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage · superDimension
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (95%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in critical care medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for critical care medicine in CA.
Geographic Context
Critical care medicines within 10 mi
23
Per 100K population
2.3
County median income
$71,434
Nearest hospital
SAINT AGNES MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Daniel is a clinical cardiology specialist, with above-average Medicare volume (top 8% in CA), with speaking/promotional industry engagement in the top 1% of CA peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Daniel experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Daniel performed 981 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Daniel receive payments from pharmaceutical companies?
Yes. Dr. Daniel received a total of $436,926 from 52 companies across 960 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Daniel's costs compare to other critical care medicines in Fresno?
Dr. Daniel's average Medicare payment per service is $88. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Daniel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Critical Care Medicines in Fresno
Browse critical care medicines in Fresno ranked by procedure volume and transparency data.
Highest volume
Top Critical Care Medicines in CA
Critical care medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Critical Care Medicines in CA
Which CA critical care medicines receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology